{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:36Z","timestamp":1793230656368,"version":"4.5.0"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Heparin is one of the most widely used drugs in the world. It has been described as a lifesaving drug due to its roles in treating many serious diseases and illnesses including kidney dialysis, surgery, cardiac-invasive, heart attack, cardiac arrhythmia, acute coronary syndrome, pulmonary embolism, stroke, deep vein thrombosis, blood clot prevention, and many other related uses. Heparin drug products currently approved in the United States are obtained from porcine intestinal mucosa sourced from pigs, the majority of which is imported from China. However, due to the heparin contamination crisis (2008) and potential shortage and to safeguard the quality of current and future heparin supply chains including raw material, Food and Drug administration (FDA) posted a notification on its website titled \u201cFDA Encourages Reintroduction of Bovine-Sourced Heparin\u201d. This perspective is intended to address the history of regulatory and scientific background of heparin drug products obtained from bovine and porcine sources and general recommendations for improving the quality of current heparin manufacturing process including Critical Quality Attributes (CQA), control management, process control, related tests, limits, etc. Additionally, a general plan with systematic steps is proposed for diversifying heparin supply chains by reintroduction of bovine sourced heparin to the US market.<\/jats:p>","DOI":"10.1177\/10760296211052293","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T06:20:45Z","timestamp":1639376445000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4403-6609","authenticated-orcid":false,"given":"Ali","family":"Al-Hakim","sequence":"first","affiliation":[{"name":"Office of New Drug Products, OPQ\/CDER\/FDA, Silver Spring, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"bibr1-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1714-3_11"},{"key":"bibr2-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(91)90098-E"},{"key":"bibr3-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1039\/c3ay40226f"},{"key":"bibr4-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1021\/ac901218q"},{"key":"bibr5-10760296211052293","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jasms.2004.05.008","volume":"15","author":"Saad OM","year":"2014","journal-title":"Journal of the American Society for Mass Spectrometry"},{"key":"bibr6-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14821"},{"key":"bibr7-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1407"},{"key":"bibr8-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3606"},{"key":"bibr9-10760296211052293","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22061025"},{"key":"bibr10-10760296211052293","unstructured":"Heparin for Drug and Medical Devices Use: Monitoring Crude Heparin for Quality.\n                      Guidance to Industry\n                      . 2013."},{"key":"bibr11-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42309-5"},{"issue":"2","key":"bibr12-10760296211052293","first-page":"334","volume":"45","author":"Mourier PA","year":"2011","journal-title":"J. Pharm. Biomed. Anal"},{"key":"bibr13-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2010.05.038"},{"key":"bibr14-10760296211052293","unstructured":"www.fortunebusinessinsights.com\/press release\/global heparin. 2020."},{"key":"bibr15-10760296211052293","unstructured":"www.repotlinker.com\/p06131415\/global-heparin-Market. 2021."},{"issue":"39","key":"bibr16-10760296211052293","author":"Szajek A","year":"2015","journal-title":"Pharm.Tech.com"},{"key":"bibr17-10760296211052293","unstructured":"www.fda.gov\/drugs\/pharmaceutical-quality-resources\/fda-encourages-reintroduction-bovine-sourced-heparin. 2018."},{"key":"bibr18-10760296211052293","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00360"},{"key":"bibr19-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1021\/jm00168a017"},{"key":"bibr20-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23501"},{"key":"bibr21-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616643822"},{"key":"bibr22-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1685164"},{"key":"bibr23-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-230"},{"key":"bibr24-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4733.4733"},{"key":"bibr25-10760296211052293","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00142"},{"key":"bibr26-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131943"},{"key":"bibr27-10760296211052293","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126075"},{"key":"bibr28-10760296211052293","unstructured":"CRC Report to the Congress. Transmissible Spongiform Encephalopathies (TSE) including Mad Cow disease: public health and scientific issues. 2004."},{"key":"bibr29-10760296211052293","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.200142"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296211052293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296211052293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296211052293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:03:02Z","timestamp":1777384982000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296211052293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["10.1177\/10760296211052293"],"URL":"https:\/\/doi.org\/10.1177\/10760296211052293","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"10760296211052293"}}